Maried Celkis, MD
Family Medicine · St Augustine, FLNPI 1194014365
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Novo Nordisk at 30.8% of the total.
Across 84 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$517
- Lilly USA, LLC$229
- GSK$204
- Otsuka America Pharmaceutical, Inc.$182
- Pfizer$141
- AbbVie$100
- plus $304 from 10 others
What the payments were for
- Food & beverage$1,677100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $517 |
| Lilly USA, LLC | 8 | $229 |
| GSK | 5 | $204 |
| Otsuka America Pharmaceutical, Inc. | 4 | $182 |
| Pfizer | 7 | $141 |
| AbbVie | 5 | $100 |
| AstraZeneca | 5 | $94 |
| BD | 1 | $36 |
| Lundbeck LLC | 2 | $34 |
| Amgen | 2 | $30 |
| Astellas Pharma US Inc | 1 | $23 |
| Novartis | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Merck | 1 | $17 |
| Vivus LLC | 1 | $17 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,677 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 145 | $167,321 |
| MounjaroTirzepatide | 78 | $98,242 |
| EliquisApixaban | 62 | $79,007 |
| RexultiBrexpiprazole | 28 | $74,847 |
| JardianceEmpagliflozin | 33 | $43,059 |
| TrulicityDulaglutide | 32 | $39,967 |
| WegovySemaglutide | 20 | $35,398 |
| Repatha SureclickEvolocumab | 37 | $30,697 |
| FarxigaDapagliflozin Propanediol | 30 | $26,524 |
| MyrbetriqMirabegron | 16 | $10,697 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $7,883 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $6,815 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $5,999 |
| SynthroidLevothyroxine Sodium | 37 | $3,622 |
| Atorvastatin Calcium | 328 | $3,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $517 | $202,719165 claims |
| Lilly USA, LLCMounjaro, Trulicity | $229 | $138,210110 claims |
| PfizerEliquis, Paxlovid | $141 | $80,43674 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $182 | $74,84728 claims |
| AstraZenecaFarxiga | $94 | $26,52430 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $10,69716 claims |
| GSKBreo Ellipta | $204 | $6,81512 claims |
| AbbVieSynthroid | $100 | $3,62237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.
Other family medicine in St Augustine
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.